Evidence map›Paper›PMID 34764237›Full record

ArticleBlood cancer journal2021

Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study.

Mirian Brink, Kaz Groen, Pieter Sonneveld, Monique C Minnema, Annemiek Broijl, Avinash G Dinmohamed, Ellen van der Spek, Mark-David Levin, Paula F Ypma, Esther de Waal and 3 more

Abstract read
In one paragraph

Article in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mirian BrinkDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. m.brink@iknl.nl.ORCID 0000-0002-6014-4810
Kaz GroenDepartment of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Pieter SonneveldDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID 0000-0002-0808-2237
Monique C MinnemaDepartment of Hematology, Cancer Center, UMC Utrecht, Utrecht, The Netherlands.ORCID 0000-0002-3139-8379
Annemiek BroijlDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Avinash G DinmohamedDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.ORCID 0000-0002-4767-6716
Ellen van der SpekDepartment of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands.
Mark-David LevinDepartment of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.ORCID 0000-0003-2139-3547
Paula F YpmaDepartment of Hematology, Haga Teaching Hospital, The Hague, The Netherlands.
Esther de WaalDepartment of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
Eduardus F M Ward PosthumaDepartment of Internal Medicine, Reinier de Graaf Group, Delft, The Netherlands.
Sonja ZweegmanDepartment of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Niels W C J van de DonkDepartment of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identification of risk factors for early mortality (EM) in multiple myeloma (MM) patients may contribute to different therapeutic approaches in patients at risk for EM. This population-based study aimed to assess trends in EM and risk factors for EM among MM patients diagnosed in the Netherlands. All MM patients, newly diagnosed between 1989 and 2018, were identified in the Netherlands Cancer Registry. Patients were categorized into three calendar periods (1989-1998, 1999-2008, 2009-2018) and into five age groups (≤65, 66-70, 71-75, 76-80, >80 years). EM was defined as death by any cause ≤180 days post-diagnosis. We included 28,328 MM patients (median age 70 years; 55% males). EM decreased from 22% for patients diagnosed in 1989-1998 to 13% for patients diagnosed in 2009-2018 (P < 0.01) and this decrease was observed among all age groups. Exact causes of death could not be elucidated. Besides patient's age, we found that features related to a more aggressive disease presentation, and patient characteristics reflecting patients' physical condition were predictive of EM. In summary, EM decreased from 1999 onwards. Nevertheless, EM remains high, especially for patients aged >70 years. Therefore, novel strategies should be explored to improve the outcome of patients at risk for EM.

Indexed as

Multiple MyelomaRegistriesAdultAgedAged, 80 and overAge FactorsFemaleFollow-Up StudiesHumansMaleMiddle AgedNetherlandsRetrospective StudiesRisk Factors

Identifiers

PMID34764237
PMCPMC8586330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.